GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » E10

Ionis Pharmaceuticals (FRA:ISI) E10 : €-0.72 (As of Sep. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was €-0.856. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.72 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was -23.40% per year. During the past 5 years, the average E10 Growth Rate was -47.30% per year. During the past 10 years, the average E10 Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Ionis Pharmaceuticals was 43.20% per year. The lowest was -65.80% per year. And the median was 5.75% per year.

As of today (2024-12-14), Ionis Pharmaceuticals's current stock price is €35.21. Ionis Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was €-0.72. Ionis Pharmaceuticals's Shiller PE Ratio of today is .


Ionis Pharmaceuticals E10 Historical Data

The historical data trend for Ionis Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals E10 Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.27 -0.26 -0.38 -0.56

Ionis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.56 -0.65 -0.67 -0.72

Competitive Comparison of Ionis Pharmaceuticals's E10

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.



Ionis Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.856/133.0289*133.0289
=-0.856

Current CPI (Sep. 2024) = 133.0289.

Ionis Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 0.203 99.070 0.273
201503 -0.129 99.621 -0.172
201506 0.258 100.684 0.341
201509 -0.267 100.392 -0.354
201512 -0.542 99.792 -0.723
201603 -0.467 100.470 -0.618
201606 -0.418 101.688 -0.547
201609 0.053 101.861 0.069
201612 0.199 101.863 0.260
201703 0.065 102.862 0.084
201706 -0.018 103.349 -0.023
201709 -0.017 104.136 -0.022
201712 0.017 104.011 0.022
201803 -0.008 105.290 -0.010
201806 -0.248 106.317 -0.310
201809 -0.026 106.507 -0.032
201812 1.943 105.998 2.438
201903 0.549 107.251 0.681
201906 -0.009 108.070 -0.011
201909 0.163 108.329 0.200
201912 1.152 108.420 1.413
202003 -0.253 108.902 -0.309
202006 -0.160 108.767 -0.196
202009 -0.153 109.815 -0.185
202012 -2.006 109.897 -2.428
202103 -0.538 111.754 -0.640
202106 -0.473 114.631 -0.549
202109 -0.493 115.734 -0.567
202112 1.248 117.630 1.411
202203 -0.418 121.301 -0.458
202206 -0.700 125.017 -0.745
202209 -0.333 125.227 -0.354
202212 -0.349 125.222 -0.371
202303 -0.813 127.348 -0.849
202306 -0.554 128.729 -0.573
202309 -0.965 129.860 -0.989
202312 -0.055 129.419 -0.057
202403 -0.902 131.776 -0.911
202406 -0.418 132.554 -0.419
202409 -0.856 133.029 -0.856

Add all the adjusted EPS together and divide 10 will get our e10.


Ionis Pharmaceuticals  (FRA:ISI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ionis Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals Headlines

No Headlines